This article is more than 5 years old. Information may no longer be current.

A Phase I/II Study Administering Peripheral Blood Lymphocytes (PBL) Transduced With a CD70-Binding Chimeric Antigen Receptor to Patients With CD70 Expressing Cancers

Issue: December 2018 2018

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Phase 1 study set to determine safety of administering PBL transduced with anti-hCD70 CAR in conjunction with lymphodepletion and high-dose interleukin-2 (IL-2; aldesleukin); Phase 2 will examine if those anti-hCD70 CAR-transduced PBL then mediate regression of tumors with CD70 expression.